CHICAGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Monroe Capital Corporation (NASDAQ: MRCC) today announced its financial results for the third quarter ended September 30, 2025. Except where the context suggests otherwise, the terms “Company,” “we,” “us,” and “our” refer to Monroe Capital Corporation (together with its subsidiaries). Third Quarter 2025 Financial Highlights Net Investment Income ("NII") of $1.8 million, or $0.08 per shareAdjusted Net Investment Income (a non-GAAP measure described below) of $1.9 mi ...

Generated revenue of $35 million, driven by strong performance of the foundational PAC business Reported Adjusted EBITDA of $5.2 million, achieving sixth consecutive quarter of positive Adjusted EBITDA Achieved 7% price increase year-over-year Achieved initial commercial phase GAC production and sales GREENWOOD VILLAGE, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products for use in purif ...

Revenue of $988 million, at the high end of guidance GAAP net income of $74 million and net income per diluted share of $1.10, each in the upper half of guidanceAdjusted EBITDA of $240 million and Non-GAAP net earnings per diluted share of $1.93, each in the upper half of guidanceOperating cash flow of $197 million and free cash flow of $147 million, enabling continued focus on the prepayment of debt and reducing net leverage ratio to 3.9x ANDOVER, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MKS Inc. (NASDAQ: ...

Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complicationsA study of people with obesity (STEP UP trial) showed that more people taking Wegovy® achieved a BMI under 27 and a waist-to-height ratio of less than 0.53, compared to non ...

JACKSONVILLE, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT) announced it will host its first-ever live video earnings call on Wednesday, November 12, 2025, at 4:30 p.m. ET, to discuss financial results for the third quarter ended September 30, 2025. Financial results will be issued via press release prior to the conference. The live-streamed event will feature prepared remarks from management followed by a Q&A session. Investors and interested ...

SKOKIE, Ill., Nov. 05, 2025 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (NASDAQ: LNZA), a leader in industrial carbon recycling, is thrilled to announce the awarding of a €40 million grant from the European Union’s Innovation Fund, subject to the finalization of the grant agreement. The project, featuring the first commercial deployment of LanzaTech’s second-generation bioreactor, aims to produce 23.5 kt (~8M U.S. gallons) of ethanol per year by consuming smelter furnace greenhouse gases (GHG) from the Porsg ...

The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan, Nov. 05, 2025 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (“PharmaCorp” or the “Company”) (TSXV: PCRX) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the “Underwriters”) co-led by Canaccord Genuity Corp. and Acumen ...

-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash equivalents, short-term investments and restricted cash of $21.0 million as of September 30, 2025 -- WESTLAKE VILLAGE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter o ...

Declares Dividend of $0.15 per share for Q3 2025Represents Genco’s 25th Consecutive Quarterly Dividend NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Genco Shipping & Trading Limited (NYSE:GNK) (“Genco” or the “Company”), the largest U.S. headquartered drybulk shipowner focused on the global transportation of commodities, today reported its financial results for the three months and nine months ended September 30, 2025. Third Quarter 2025 and Year-to-Date Highlights Dividend Declared a $0.15 per share dividend ...

SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate the study.Following the positive SAD/MAD data results announced in September for SCY-247, its second-generation fungerp, the Company expects to initiate a Phase 1 study with the IV formulation and a Phase 2 study for the treatment of invasive candidiasis. The Company aims t ...